AR041589A1 - PERIPHERALLY SELECTIVE DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION - Google Patents

PERIPHERALLY SELECTIVE DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION

Info

Publication number
AR041589A1
AR041589A1 ARP030103711A ARP030103711A AR041589A1 AR 041589 A1 AR041589 A1 AR 041589A1 AR P030103711 A ARP030103711 A AR P030103711A AR P030103711 A ARP030103711 A AR P030103711A AR 041589 A1 AR041589 A1 AR 041589A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
term
preparation
alkyloxy
Prior art date
Application number
ARP030103711A
Other languages
Spanish (es)
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of AR041589A1 publication Critical patent/AR041589A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos con propiedades farmacéuticas potencialmente valiosas para el tratamiento de trastornos cardiovasculares tales como la hipertensión y la insuficiencia cardíaca crónica. También reivindica, composición farmacéutica, uso para preparación de medicamentos, procesos e intermediarios. Reivindicación 1: Un compuesto de fórmula (1) donde R1, R2, y R3 son iguales o diferentes y significan hidrógenos, halógenos, grupo alquilo, alquiloxi, hidroxi, nitro, amino, alquilcarbonilamino, alquilamino o dialquilamino; R4 significa H, grupo alquilo o alquilarilo; X significa CH2, átomo de O o átomo de S; n es 1, 2 o 3, con la condición de que cuando n es 1, X no es CH2; y los enantiómeros ( R )y (S) individuales o mezclas de enantiómeros y sus sales farmacéuticamente aceptables; donde el término alquilo significa cadenas de hidrocarburos, rectas o ramificadas que contienen entre 1 y 6 átomos de C, opcionalmente sustituidas con grupos arilo, alcoxi, halógeno, alcoxicarbonilo o hidroxicarbonilo; el término arilo significa un grupo fenilo o naftilo, opcionalmente sustituido con un grupo alquiloxi, halógeno o nitro; el término halógeno significa F, Cl, Br, o I .Compounds with potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure. It also claims, pharmaceutical composition, use for preparation of medicines, processes and intermediaries. Claim 1: A compound of formula (1) wherein R1, R2, and R3 are the same or different and mean hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino groups; R4 means H, alkyl or alkylaryl group; X means CH2, O atom or S atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2; and the individual (R) and (S) enantiomers or mixtures of enantiomers and their pharmaceutically acceptable salts; where the term "alkyl" means straight or branched hydrocarbon chains containing between 1 and 6 C atoms, optionally substituted with aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term "aryl" means a phenyl or naphthyl group, optionally substituted with an alkyloxy, halogen or nitro group; the term halogen means F, Cl, Br, or I.

ARP030103711A 2002-10-11 2003-10-10 PERIPHERALLY SELECTIVE DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION AR041589A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Publications (1)

Publication Number Publication Date
AR041589A1 true AR041589A1 (en) 2005-05-26

Family

ID=9945777

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030103711A AR041589A1 (en) 2002-10-11 2003-10-10 PERIPHERALLY SELECTIVE DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION
ARP140101283A AR095674A2 (en) 2002-10-11 2014-03-18 PERIPHERALLY SELECTIVE DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140101283A AR095674A2 (en) 2002-10-11 2014-03-18 PERIPHERALLY SELECTIVE DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION

Country Status (11)

Country Link
KR (1) KR101350741B1 (en)
CN (1) CN100393715C (en)
AR (2) AR041589A1 (en)
AT (5) ATE505465T1 (en)
CY (2) CY1108452T1 (en)
DE (4) DE60336276D1 (en)
DK (2) DK1908760T3 (en)
ES (5) ES2384118T3 (en)
GB (2) GB2393958A (en)
HK (1) HK1116188A1 (en)
SI (2) SI1408038T1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
EP2655363B1 (en) * 2010-12-22 2017-04-12 Bial-Portela & CA, S.A. Crystalline forms and processes for their preparation
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
CZ290082B6 (en) * 1994-04-26 2002-05-15 Syntex (U. S. A.) Inc. Benzocycloalkylazolethione derivatives, pharmaceutical preparation containing thereof, process of their preparation and intermediates of the preparation process

Also Published As

Publication number Publication date
GB2394223B (en) 2007-05-16
CY1108452T1 (en) 2014-04-09
AR095674A2 (en) 2015-11-04
DK1908760T3 (en) 2011-07-25
ES2384118T3 (en) 2012-06-29
DE60336276D1 (en) 2011-04-14
DE60336772D1 (en) 2011-05-26
DE60336275D1 (en) 2011-04-14
GB0224306D0 (en) 2002-11-27
CY1112457T1 (en) 2015-12-09
SI1908760T1 (en) 2011-05-31
CN100393715C (en) 2008-06-11
ATE500248T1 (en) 2011-03-15
KR20120038014A (en) 2012-04-20
ATE550335T1 (en) 2012-04-15
DK1408038T3 (en) 2008-11-24
ATE505465T1 (en) 2011-04-15
GB2394223A (en) 2004-04-21
HK1116188A1 (en) 2008-12-19
ATE403652T1 (en) 2008-08-15
ES2361939T3 (en) 2011-06-24
ATE500247T1 (en) 2011-03-15
GB2393958A (en) 2004-04-14
GB0223719D0 (en) 2002-11-20
KR101350741B1 (en) 2014-01-10
CN1726211A (en) 2006-01-25
SI1408038T1 (en) 2008-10-31
ES2309279T3 (en) 2008-12-16
DE60322642D1 (en) 2008-09-18
ES2364919T3 (en) 2011-09-16
ES2361938T3 (en) 2011-06-24

Similar Documents

Publication Publication Date Title
UY26086A1 (en) PROCEDURES AND INTERMEDIATES TO PREPARE ANTI-CANCER COMPOUNDS
UY28374A1 (en) THERAPEUTIC AGENTS
ECSP066667A (en) SPIROCICLIC CYCLHEXAN DERIVATIVES
AR047531A1 (en) DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS
UY28144A1 (en) THERAPEUTIC AGENTS
ES2190396T3 (en) NEW AMINO-TRIAZOL COMPOUNDS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ECSP045229A (en) PIRIDINONES REPLACED AS MODULATORS OF THE P38 MAP QUINASA
CU23413B7 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
CO4810373A1 (en) ARYL-CONDENSED AZAPOLYCLIC COMPOUNDS
CO5540385A2 (en) OXAZOL ARILPROPIONIC ACID CHIRAL DERIVATIVES, THEIR SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR066457A1 (en) IMIDAZOL DERIVATIVES, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES.
UY27803A1 (en) DERIVATIVES OF BENZOXAZINE AND USES OF THE SAME.
AR054813A1 (en) DERIVATIVES OF PIRROLOQUINOLINAS AND ITS USES AS INHIBITORS OF KINASE PROTEINS
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PA8589801A1 (en) AMINOALCOXYINDOLS
AR051149A1 (en) BENZOTIADIAZINE COMPOUNDS, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR040579A1 (en) ENAMIDA PHENYLALANINE DERIVATIVES
AR095674A2 (en) PERIPHERALLY SELECTIVE DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION
MX9304424A (en) BENZIMIDAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
UY27770A1 (en) IMIDAZOLINILMETIL ARALQUILSULFONAMIDAS
AR003977A1 (en) ENDOPARASTIC COMPOSITIONS BASED ON DIDEPSIPEPTIDES, NEW DIDEPSIPEPTIDES AND PROCEDURES FOR THEIR PRODUCTION.
AR034861A1 (en) AN INDENOINDOLONE COMPOUND, A PROCEDURE FOR THE PREPARATION AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR045515A1 (en) PROCEDURE FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
AR045517A1 (en) PROCEDURE FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
AR037140A1 (en) A COMPOUND OF AMINOPIRROL, ITS USE, A PROCEDURE TO PRODUCE IT AND A COMPOSITION THAT INCLUDES IT

Legal Events

Date Code Title Description
FG Grant, registration